secwatch.observer — SEC 8-K summary
======================================

Issuer:     TransMedics Group, Inc. (TMDX)
CIK:        0001756262
Form:       8-K
Filed at:   2024-10-28T23:59:59+00:00
Accession:  0000950170-24-117727
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransMedics Q3 revenue $108.8M (+64% YoY), net income $4.2M; FY guidance reaffirmed
--------------------------------------------------------------------------------

- Total revenue $108.8M, up 64% from $66.4M in Q3 2023.
- Net income $4.2M ($0.12 diluted EPS) vs net loss of $25.4M in prior year.
- Gross margin 56% vs 61% a year ago due to shift to service revenue.
- FY 2024 revenue guidance reaffirmed at $425M–$445M (76–84% growth).
- Cash $330.1M as of Sep 30; owned 18 aircraft for the National OCS Program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1756262/000095017024117727/0000950170-24-117727-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1756262/000095017024117727/tmdx-20241028.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-117727

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer